MedPage Today -- VIENNA -- Development of a heat-stable protease inhibitor combination of lopinavir/ritonavir (Kaletra) allowed the combination product to virtually take over as the second-line treatment of choice for people infected with HIV in low- to-middle-income countries, an analysis has found.
